Categories: Technology

PROACTIS SA – Press Release (nomination C. Carter and P. Shepherd) 19.12.2025

Press Release

Evolution of PROACTIS SA Governance

PARIS, France – (19 December 2025) — Under the terms of the Board of Directors of the company PROACTIS SA (ISIN code: FR0004052561) held on the 18th of December 2025, Mrs. Charlotte CARTER has been appointed as Director in replacement of Mrs. Bonnie MITCHELL, resigning.

Charlotte Carter joined Proactis in 2013. She is Vice President for Product at Proactis, where she leads a high-performing team dedicated to investing in our next generation of software products. She brings over 12 years of experience in the Source-to-Pay software domain, with expertise in procurement, spend control and SaaS and is supported by CIPS certification and executive education from MIT Sloan.

During this same meeting, Mr. Peter SHEPHERD has been appointed as Director in replacement of Mr. Graham DAVIS, resigning.

Peter Shepherd joined Proactis in November 2025 after being CFO at Medical Management Systems LTD. He brings over 20 years of experience in senior financial roles, with strong expertise in strategy, growth management, and financial excellence within international organizations. His experience and leadership will be instrumental in helping Proactis Group continue its evolution.

Shareholders will be asked to approve these appointments at the next Annual General Meeting called to approve the financial statements for the year ended January 31st, 2026.

As a result of these changes, the Board of Directors of PROACTIS SA is now composed as follows:

Member Functions Mandate expiry date
Andrew REARDON Chairman of the Board of Directors
Chief Executive Officer
Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Charlotte CARTER Director Annual General Meeting to approve the financial statements for the year ending January 31, 2030
Peter SHEPHERD Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028
Maria LARSEN Director Annual General Meeting to approve the financial statements for the year ending January 31, 2028

* * * *

Contacts
Tel: +33 (0)1 53 25 55 00
E-mail: investorContact@proactis.com

* * * *

GlobeNews Wire

Recent Posts

Blockchain.com Unveils Highly Anticipated Crypto-Backed Loans, Bringing Borrowing To Crypto Holders Worldwide

The company launches in-house lending for global users starting at 1.9%, delivering one of the…

15 minutes ago

Artmarket.com: The Artprice Manifesto: 22 Rules for a Regulated and Transparent Art Market in the Age of AI

Artificial intelligence is redistributing the value of information at an unprecedented pacePARIS, May 14, 2026…

15 minutes ago

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

9 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

9 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

9 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

9 hours ago